The enhanced precision used in 3DP can drive efficiencies in early drug development by allowing more flexibility with dosage size and strengths, leading to a more responsible use of precious and costly resources.
To address the limitations of oral solid dose forms while also keeping pace with advances in patient treatment, pharmaceutical manufacturers must be willing to consider alternative approaches to developing and manufacturing OSD drugs.
Securing a partner to serve as an extension of Janssen’s Biotherapeutics Development API-Large Molecule team was essential to reducing both risk and the time needed for delivery of critical clinical supplies.
3D printing allows drug companies to not only boost efficacy and adherence but also contribute to their brand longevity by expanding and capturing market share with other dosage form options.
By applying remote monitoring solutions, advanced modeling, and optimization of manufacturing processes, Industry 4.0 offers improved process reliability and product quality through unlimited possibilities of connecting machines and data.
Cory Card, Principal Scientist at GE, discusses not just ideas shared at a recent industry symposium on raw material variability control, but, most importantly, where to go from here.
Larger pharma organization have evolved into hierarchical silos due to a combination of legacy organizational structures, mergers and acquisitions, and lack of a holisitic approach to innovation.
Using its Supplier Relationship Excellence (SRE) program, Amgen opened the lines of communication with suppliers and created a feedback loop where data can be shared to better understand operational performance.
Companies must understand how today’s new pharmaceutical landscape is causing a dramatic shift in how we plan for and execute drug development and manufacturing.
Pharma and biotech companies have invested heavily in externalized research, development, and manufacturing in recent years – but their methods of sharing critical data are still rarely fit for purpose.